Affimed Provides Follow-up Data of AFM24 plus Atezolizumab S

Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort

In 17 EGFR wild-type non-small cell lung cancer patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 of 4 responses were ongoing for more than 7...

Related Keywords

Seoul , Soult Ukpyolsi , South Korea , Ukraine , Germany , Texas , United States , Mannheim , Baden Wüberg , Artiva Allo , Alexander Fudukidis , Mary Beth Sandin , Andreas Harstrick , Hye Ryun Kim , Yonsei University College Of Medicine , University Of Texas Md Anderson Cancer Center , Globenewswire Inc , Chief Medical , Chief Executive Officer , Gryun Kim , University College , Cancer Center ,